Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01510912 · ClinicalTrials.gov registry record · Phase 3

Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain

A Phase 3 study, sponsored by Iroko Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
602
Enrollment target

NCT01510912 is a Phase 3 study that has completed, run by Iroko Pharmaceuticals. The registered enrollment target is 602 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01510912, a Phase 3 study, has completed, sponsored by Iroko Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
602 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety of Diclofenac \[Test\] Capsules for the treatment of osteoarthritis pain of the knee or hip.

Interventions

  • DRUG Diclofenac

Trial Details

FieldValue
Enrollment Target 602 participants
Start Date 2012-01
Est. Completion 2013-03
Phase Phase 3

Sponsor

Iroko Pharmaceuticals

12 total trials

What the Registry Record Tells You About NCT01510912

The ClinicalTrials.gov registry entry for NCT01510912 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 602 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Iroko Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Diclofenac is the first listed.

NCT01510912 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01510912 about?

NCT01510912 is a clinical study titled "Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain". The purpose of this study is to evaluate the safety of Diclofenac \[Test\] Capsules for the treatment of osteoarthritis pain of the knee or hip.

What is the current status of trial NCT01510912?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 602 participants. The study started on 2012-01. Estimated completion is 2013-03.

What interventions are being tested in trial NCT01510912?

The interventions under investigation include: Diclofenac (DRUG).

Who is sponsoring clinical trial NCT01510912?

This trial is sponsored by Iroko Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.